The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Saginbaev U.R.

I.P. Pavlov First St. Petersburg State Medical University

Laboratory considerations in assessing efficacy and safety of biologic therapy in the elderly (as Exemplified by Asthma)

Authors:

Saginbaev U.R.

More about the authors

Journal: Laboratory Service. 2025;14(2): 29‑32

DOI: 10.17116/labs20251402129

Read: 704 times

Download PDF (RU)
Contact the author
Table of contents

LABORATORY CONSIDERATIONS IN ASSESSING EFFICACY AND SAFETY OF BIOLOGIC THERAPY IN THE ELDERLY (AS EXEMPLIFIED BY ASTHMA)
LABORATORY CONSIDERATIONS IN ASSESSING EFFICACY AND SAFETY OF BIOLOGIC THERAPY IN THE ELDERLY (AS EXEMPLIFIED BY ASTHMA)

To cite this article:

Saginbaev UR. Laboratory considerations in assessing efficacy and safety of biologic therapy in the elderly (as Exemplified by Asthma). Laboratory Service. 2025;14(2):29‑32. (In Russ.)
https://doi.org/10.17116/labs20251402129

Подписка 2025 Лабораторная служба (Laboratory Service)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Treatment of benign fami­lial chro­nic pemphigus with omalizumab. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):72-80
Effi­cacy of dupi­lumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):204-209
Neutrophil elastase as a promising biomarker of low-grade inflammation in chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(4):142-148
Syne­rgistic effi­ciency of preformed physical factors and dupi­lumab in the treatment of poly­pous rhinosinusitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):16-23
Rela­tionship between oxidative stress patterns and proinflammatory cyto­kines in patients with poly­pous rhinosinusitis under the course of therapeutic physical factors. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):42-49
Recu­rrent pain syndromes in adolescents of different ages. Russian Journal of Pain. 2025;(2):24-31
Asso­ciation of the ischemic heart disease with blood pressure, age and work expe­rience in men with shift work in the Far North. Russian Journal of Preventive Medi­cine. 2025;(8):34-40
Sex and age characteristics of stroke risk factors in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):89-97
Influence of age and sex on values of SNOT-22 sino­nasal test domains in children and adolescents with bronchial asthma. Russian Rhinology. 2025;(3):197-204
Abstract:

Severe bronchial asthma is characterized by a complex pathogenesis, the key links of which are inflammation and allergic reactions. A promising method of treating this nosology is considered to be targeted genetically engineered biological therapy aimed at different targets (cytokines, receptor, or other components of cell signaling) of pathogenesis. However, few studies have investigated the efficacy and safety of monoclonal antibody treatment in the elderly. Meanwhile, aging is also characterized by a specific inflammatory background — inflamaging, which can significantly affect the diagnosis and treatment of the disease. The review summarizes the data of the current literature on the criteria for the effectiveness of treatment with targeted therapy drugs, and also considers promising laboratory candidate markers that have the potential to be a predictor of the effectiveness of therapy for severe bronchial asthma among people over 60 years of age.

Keywords:

asthma
age
omalizumab
dupilumab
inflamaging

Authors:

Saginbaev U.R.

I.P. Pavlov First St. Petersburg State Medical University

Received:

12.04.2025

Accepted:

04.05.2025

Close metadata

References:

  1. Sun L, Wang X, Saredy J, Yuan Z, Yang X, Wang H. Innate-adaptive immunity interplay and redox regulation in immune response. Redox Biol. 2020;37:101759. https://doi.org/10.1016/j.redox.2020.101759
  2. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590.  https://doi.org/10.1038/s41574-018-0059-4
  3. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902.  https://doi.org/10.1016/j.jaci.2014.08.042
  4. Silkoff PE, Moore WC, Sterk PJ. Three Major Efforts to Phenotype Asthma: Severe Asthma Research Program, Asthma Disease Endotyping for Personalized Therapeutics, and Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome. Clin Chest Med. 2019;40(1):13-28.  https://doi.org/10.1016/j.ccm.2018.10.016
  5. Striz I, Golebski K, Strizova Z, Loukides S, Bakakos P, Hanania NA, Jesenak M, Diamant Z. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023;137(9):727-753.  https://doi.org/10.1042/CS20190281
  6. Liaqat A, Mason M, Foster B, Gregory G, Patel A, Barlas A, Kulkarni S, Basso R, Patak P, Liaqat H, Qureshi M, Shehata A, Awad Y, Ghaly M, Gulzar Q, Doty W. Evidence-Based Approach of Biologic Therapy in Bronchial Asthma. J Clin Med. 2023;12(13):4321. https://doi.org/10.3390/jcm12134321
  7. Ji H, Tan LD, Hafzalla GW, Nguyen N, Alismail A. Navigating biologic therapies in elderly asthma. Respir Med. 2024;227:107655. https://doi.org/10.1016/j.rmed.2024.107655
  8. Rodichkina V, Kvetnoy I, Polyakova V, Arutjunyan A, Nasyrov R, Ivanov D. Inflammaging of Female Reproductive System: A Molecular Landscape. Curr Aging Sci. 2021;14(1):10-18.  https://doi.org/10.2174/1874609813666200929112624
  9. Zhang M, Jin M, Zhou X, Lin J, Liu X, Liu C, Huang M, Wang W, Chen L, Huang Y, Li J, Zhang Q, Shen H, Yu Y, Tang W, Zhou J, Liu H, Dong L, Hu Y, Wu H, Li Y, Song W, Ouyang M, Yuan X, Wang T, Xiong S. Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China. Respir Med. 2021;186:106522. https://doi.org/10.1016/j.rmed.2021.106522
  10. Kato A, Kamata M, Ito M, Uchida H, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y. Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis. J Dermatol. 2020;47(9):1013-1019. https://doi.org/10.1111/1346-8138.15464
  11. Keskinkaya Z, Kaya O, Isık Mermutlu S, Ogretmen Z. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2024;185(8):786-793.  https://doi.org/10.1159/000538291
  12. Hur GY, Ye YM, Yang E, Park HS. Serum potential biomarkers according to sputum inflammatory cell profiles in adult asthmatics. Korean J Intern Med. 2020;35(4):988-997.  https://doi.org/10.3904/kjim.2019.083
  13. Chen J, Ou S, Wu W, Zou H, Li H, Zhu H. Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome. Clin Cosmet Investig Dermatol. 2024;17:1799-1808. https://doi.org/10.2147/CCID.S470160
  14. Norzila MZ, Fakes K, Henry RL, Simpson J, Gibson PG. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. Am J Respir Crit Care Med. 2000;161:769-774.  https://doi.org/10.1164/ajrccm.161.3.9809071
  15. Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A, Rossi A, Ricciardolo FL. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy. 2006;36(11):1373-1381. https://doi.org/10.1111/j.1365-2222.2006.02502.x
  16. Tiotiu A. Biomarkers in asthma: state of the art. Asthma Res Pract. 2018;4:10.  https://doi.org/10.1186/s40733-018-0047-4
  17. An J, Lee JH, Sim JH, Song WJ, Kwon HS, Cho YS, Moon HB, Kim CK, Kim TB. Serum Eosinophil-Derived Neurotoxin Better Reflect Asthma Control Status Than Blood Eosinophil Counts. J Allergy Clin Immunol Pract. 2020;8(8):2681-2688. https://doi.org/10.1016/j.jaip.2020.03.035
  18. Tsuda T, Maeda Y, Nishide M, Koyama S, Hayama Y, Nojima S, Takamatsu H, Okuzaki D, Kinehara Y, Kato Y, Nakatani T, Obata S, Akazawa H, Shikina T, Takeda K, Hayama M, Inohara H, Kumanogoh A. Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity. Int Immunol. 2019;31(1):33-40.  https://doi.org/10.1093/intimm/dxy061
  19. Decaesteker T, Seys S, Hox V, Dilissen E, Marijsse G, Manhaeghe L, Hellings P, Vanoirbeek J, Bullens D, Dupont L. Serum and sputum calprotectin, a reflection of neutrophilic airway inflammation in asthmatics after high-altitude exposure. Clin Exp Allergy. 2017;47(12):1675-1677. https://doi.org/10.1111/cea.13043
  20. de Vries R, Dagelet YWF, Spoor P, Snoey E, Jak PMC, Brinkman P, Dijkers E, Bootsma SK, Elskamp F, de Jongh FHC, Haarman EG, In ‘t Veen JCCM, Maitland-van der Zee AH, Sterk PJ. Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. Eur Respir J. 2018;51(1):1701817. https://doi.org/10.1183/13993003.01817-2017
  21. Takahashi K, Meguro K, Kawashima H, Kashiwakuma D, Kagami SI, Ohta S, Ono J, Izuhara K, Iwamoto I. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019;56(3):236-243.  https://doi.org/10.1080/02770903.2018.1455855
  22. Wan XC, Woodruff PG. Biomarkers in Severe Asthma. Immunol Allergy Clin North Am. 2016;36(3):547-557.  https://doi.org/10.1016/j.iac.2016.03.004
  23. Gazizova GR, Valeeva FV, Gajsina LR. Mochevaja jekskrecija interlejkina-1β, monocitarnogo hemoattraktantnogo proteina-1 i transformirujushhego faktora rosta-β1 u beremennyh s saharnym diabetom 1 tipa s raznym urovnem jekskrecii al’bumina s mochoj. Medicinskij vestnik Juga Rossii. 2015;(1):44-50. (In Russ.). https://doi.org/10.21886/2219-8075-2015-1-44-50
  24. Kravchenko ES, Suslova TE, Kologrivova IV, Koshel’skaja OA. Jeotaksin i serdechno-lodyzhechnyj sosudistyj indeks u pacientov vysokogo i ochen’ vysokogo serdechno-sosudistogo riska. Medicinskaja immunologija. 2023;25(4):971-976. (In Russ.). https://doi.org/10.15789/1563-0625-EAC-2768
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.